Ovarian Carcinoma Clinical Trials in New York, New York
8 studies are recruiting for ovarian carcinoma in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Memorial Sloan Kettering Hospital, New York, New York
- Locations
- 90 in total
- Run by
- Daiichi Sankyo
-
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- NYU Langone Medical Center, New York, New York
- Locations
- 16 in total
- Run by
- A2 Biotherapeutics Inc.
-
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may hel…
- Stage
- Phase 1
- Ages
- 1 to 30
- Site
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
- Locations
- 21 in total
- Run by
- Children's Oncology Group
-
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salp…
- Stage
- Not phased
- Ages
- 35 to 50
- Site
- Mount Sinai Chelsea, New York, New York
- Locations
- 574 in total
- Run by
- NRG Oncology
-
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibi…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Mount Sinai Chelsea, New York, New York
- Locations
- 695 in total
- Run by
- NRG Oncology
-
A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
The purpose of this study is to see if propranolol and etodolac along with mind-body resilience training/MBRT and music therapy help participants who are experiencing physiological stress before, during, and after primary debulking surgery/PDS or IDS and also if it's better than the standard-of-car…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
- Locations
- 7 in total
- Run by
- Memorial Sloan Kettering Cancer Center
-
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumours that are likely to be FAP positive. The study consists of an initial Phase …
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Memorial Sloan Kettering Cancer Center, New York, New York
- Locations
- 9 in total
- Run by
- Avacta Life Sciences Ltd
-
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Participants will be scheduled for primary cytoreductive surgery as part of their standard care. Before surgery, participants will be assigned by chance to a study group. Depending on which group they are in, they will receive either acute normovolemic hemodilution/ANH during surgery or standard su…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York, New York
- Locations
- 7 in total
- Run by
- Memorial Sloan Kettering Cancer Center
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.